Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Inclusion Criteria: * Ability to provide informed consent and comply with study assessment for the duration of one year * Age \>= 25 years * Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision * BCVA using ETDRS 20/32 to 20/400 Exclusion Criteria: * Any history of previous vitrectomy * Previous cataract or ocular surgery within 2 months of day 0 * Active intraocular inflammation in the study eye * Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Participation with another investigational drug within the past 30 days * Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry * Blood pressure \>180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable) * Pregnancy